2021
DOI: 10.1097/mnh.0000000000000726
|View full text |Cite
|
Sign up to set email alerts
|

SNF472: mechanism of action and results from clinical trials

Abstract: Purpose of reviewVascular calcification (VC) is associated with increased cardiovascular event rates, particularly in patients with end-stage kidney disease (ESKD). Dysregulated mineral metabolism and inflammation have been shown to promote VC, however, treatment options targeting VC specifically are not available. This review outlines the pathophysiological mechanisms contributing to VC in ESKD and describes recent studies evaluating the effects of the first-in-class inhibitor of VC, SNF472.Recent findingsSNF… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 35 publications
0
5
0
Order By: Relevance
“…24 The pathophysiological alteration caused by the arterial stiffening in media sclerosis assists to systolic hypertension and congestive heart failure. 25 The incidence and prognosis of cardiovascular events should be significantly improved via preventing or rescuing pathogenesis of VC.…”
Section: Discussionmentioning
confidence: 99%
“…24 The pathophysiological alteration caused by the arterial stiffening in media sclerosis assists to systolic hypertension and congestive heart failure. 25 The incidence and prognosis of cardiovascular events should be significantly improved via preventing or rescuing pathogenesis of VC.…”
Section: Discussionmentioning
confidence: 99%
“…Phytate is a potential nutrient for VC treatment 297 . SNF472, which acts as an exogenous source of phytate, exerts an inhibitory effect on VC 298–300 . The clinical trial proved that an adequate prescription of phytate can protect against AAC in CKD patients 301 .…”
Section: Potential Therapeutic Strategies Of Vcmentioning
confidence: 96%
“… 297 SNF472, which acts as an exogenous source of phytate, exerts an inhibitory effect on VC. 298 , 299 , 300 The clinical trial proved that an adequate prescription of phytate can protect against AAC in CKD patients. 301 Inositol hexakisphosphate (IP6, phytic acid), an endogenous compound existing widespread in mammalian cells or tissues, inhibits the mineralization of osteoblast cultures to protect against VC.…”
Section: Potential Therapeutic Strategies Of Vcmentioning
confidence: 99%
“…Currently, numerous methods exist to decrease vascular calcification in dialysis patients, such as the utilization of vitamin K1 [ 66 ], subcutaneous insulin and heparin [ 67 ], as well as the use of sodium thiosulfate [ 68 ], bisphosphonate [ 69 ], and inositol hexaphosphate hexasodium salt (SNF) 472 [ 70 ]. These drugs have been tested for treating vascular calcification in dialysis patients and have proven to be effective.…”
Section: Risk Factor Management Of Hf In Dialysis Patientsmentioning
confidence: 99%